4.8 Article

A Genomics-Based Classification of Human Lung Tumors

期刊

SCIENCE TRANSLATIONAL MEDICINE
卷 5, 期 209, 页码 -

出版社

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.3006802

关键词

-

资金

  1. EU-Framework Programme CURELUNG [HEALTH-F2-2010-258677]
  2. Deutsche Forschungsgemeinschaft [TH1386/3-1, SFB832, TP6, TP5, SB680]
  3. German Ministry of Science and Education as part of the NGFNplus program [01GS08100, 01GS08101]
  4. Deutsche Krebshilfe as part of the Oncology Centers of Excellence funding program
  5. SyBaCol
  6. Max Planck Society
  7. Behrens-Weise Foundation (M.I.F.A.) [NEUR8061]
  8. Stand Up To Cancer-American Association for Cancer Research Innovative Research Grant [SU2C-AACR-IR60109]
  9. Roy Castle Lung Cancer Foundation UK
  10. German Centre for Lung Research [82DZL00402]
  11. DFG
  12. Ministry of Research of the State of North Rhine-Westphalia

向作者/读者索取更多资源

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Public, Environmental & Occupational Health

Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program

Hilary A. Robbins, Karine Alcala, Elham Khodayari Moez, Florence Guida, Sera Thomas, Hana Zahed, Matthew T. Warkentin, Karl Smith-Byrne, Yonathan Brhane, David Muller, Xiaoshuang Feng, Demetrius Albanes, Melinda C. Aldrich, Alan A. Arslan, Julie Bassett, Christine D. Berg, Qiuyin Cai, Chu Chen, Michael P. A. Davies, Brenda Diergaarde, John K. Field, Neal D. Freedman, Wen-Yi Huang, Mikael Johansson, Michael Jones, Woon-Puay Koh, Stephen Lam, Qing Lan, Arnulf Langhammer, Linda M. Liao, Geoffrey Liu, Reza Malekzadeh, Roger L. Milne, Luis M. Montuenga, Thomas Rohan, Howard D. Sesso, Gianluca Severi, Mahdi Sheikh, Rashmi Sinha, Xiao-Ou Shu, Victoria L. Stevens, Martin C. Tammemaegi, Lesley F. Tinker, Kala Visvanathan, Ying Wang, Renwei Wang, Stephanie J. Weinstein, Emily White, David Wilson, Jian-Min Yuan, Xuehong Zhang, Wei Zheng, Christopher I. Amos, Paul Brennan, Mattias Johansson, Rayjean J. Hung

Summary: The INTEGRAL program aims to develop tools for optimizing LDCT lung cancer screening. It includes the Risk Biomarker and Nodule Malignancy projects, which investigate circulating protein markers for identifying individuals likely to benefit from screening and distinguishing benign versus malignant nodules. A total of 1161 and 1078 proteins were measured, and 21 proteins were selected for performance evaluation in the Risk Biomarker and Nodule Malignancy projects.

ANNALS OF EPIDEMIOLOGY (2023)

Article Oncology

Occupational exposure to nickel and hexavalent chromium and the risk of lung cancer in a pooled analysis of case-control studies (SYNERGY)

Thomas Behrens, Calvin Ge, Roel Vermeulen, Benjamin Kendzia, Ann Olsson, Joachim Schuez, Hans Kromhout, Beate Pesch, Susan Peters, Luetzen Portengen, Per Gustavsson, Dario Mirabelli, Pascal Guenel, Daniele Luce, Dario Consonni, Neil E. Caporaso, Maria Teresa Landi, John K. Field, Stefan Karrasch, Heinz-Erich Wichmann, Jack Siemiatycki, Marie-Elise Parent, Lorenzo Richiardi, Lorenzo Simonato, Karl-Heinz Joeckel, Wolfgang Ahrens, Hermann Pohlabeln, Guillermo Fernandez-Tardon, David Zaridze, John R. McLaughlin, Paul A. Demers, Beata Swiatkowska, Jolanta Lissowska, Tamas Pandics, Eleonora Fabianova, Dana Mates, Vladimir Bencko, Lenka Foretova, Vladimir Janout, Paolo Boffetta, Bas Bueno-de-Mesquita, Francesco Forastiere, Kurt Straif, Thomas Bruening

Summary: Limited evidence exists regarding the exposure-effect relationship between lung-cancer risk and hexavalent chromium (Cr(VI)) or nickel. This study found that occupational exposure to Cr(VI) and nickel was associated with lung-cancer risks, particularly in men. In men, the highest quartile of cumulative exposure to CR(VI) and nickel were both significantly associated with increased odds ratios for lung cancer.

INTERNATIONAL JOURNAL OF CANCER (2023)

Article Oncology

Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic

Volker Arndt, Daniela Doege, Stefan Froehling, Peter Albers, Hana Alguel, Ralf Bargou, Carsten Bokemeyer, Martin Bornhaeuser, Christian H. Brandts, Peter Brossart, Sara Yvonne Brucker, Tim H. Bruemmendorf, Hartmut Doehner, Norbert Gattermann, Michael Hallek, Volker Heinemann, Ulrich Keilholz, Thomas Kindler, Cornelia von Levetzow, Florian Lordick, Ulf Peter Neumann, Christoph Peters, Dirk Schadendorf, Stephan Stilgenbauer, Thomas Zander, Daniel Zips, Delia Braun, Thomas Seufferlein, Gerd Nettekoven, Michael Baumann

Summary: The capacities of German Comprehensive Cancer Centers (CCCs) in various aspects of oncology care were significantly affected during the first 2 years of the COVID-19 pandemic. Follow-up, psycho-oncologic care, and tumor surgery were particularly impacted, along with other areas of multidisciplinary oncological care. This study highlights the importance of developing strategies to prevent similar limitations in the future.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

Letter Genetics & Heredity

A novel MAP3K20 mutation causing centronuclear myopathy-6 with fiber-type disproportion in a Pakistani family

Ilyas Ahmad, Ayaz Khan, Hafiza Noor Ul Ayan, Birgit Budde, Janine Altmueller, Asad Aslam Korejo, Gudrun Nurnberg, Holger Thiele, Muhmmad Tariq, Peter Nuernberg, Jeanette Erdmann

JOURNAL OF HUMAN GENETICS (2023)

Article Hematology

Characteristics and outcomes of patients undergoing high-dose chemotherapy and autologous stem cell transplantation admitted to the intensive care unit: a single-center retrospective analysis

Jorge Garcia Borrega, Boris Boell, Matthias Kochanek, Jan-Hendrik Naendrup, Florian Simon, Noelle Sieg, Michael Hallek, Peter Borchmann, Udo Holtick, Alexander Shimabukuro-Vornhagen, Dennis A. Eichenauer, Jan-Michel Heger

Summary: A retrospective analysis was conducted on patients admitted to the intensive care unit (ICU) during hospitalization for high-dose chemotherapy and autologous stem cell transplantation (ASCT). The study found that the overall outcome was favorable for these patients.

ANNALS OF HEMATOLOGY (2023)

Article Oncology

Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients

Nadine Kutsch, Emily Eva Holmes, Sandra Robrecht, Gudrun Schueler, Ursula Vehling-Kaiser, Thomas Decker, Sigrun Mueller-Hagen, Karin Heinisch, Sebastian Boettcher, Matthias Ritgen, Karl-Anton Kreuzer, Stephan Stilgenbauer, Anna Maria Fink, Kirsten Fischer, Barbara Eichhorst, Michael Hallek, Clemens-Martin Wendtner

LEUKEMIA & LYMPHOMA (2023)

Article Oncology

A trans-omics assessment of gene-gene interaction in early-stage NSCLC

Jiajin Chen, Yunjie Song, Yi Li, Yongyue Wei, Sipeng Shen, Yang Zhao, Dongfang You, Li Su, Maria Moksnes Bjaanaes, Anna Karlsson, Maria Planck, Johan Staaf, Aslaug Helland, Manel Esteller, Hongbing Shen, David C. C. Christiani, Ruyang Zhang, Feng Chen

Summary: This study identified significant gene-gene interactions associated with non-small-cell lung cancer survival through a three-step analytic strategy. Two interactions were found at both the epigenetic and transcriptional levels, providing potential clues for precision treatment of NSCLC.

MOLECULAR ONCOLOGY (2023)

Article Oncology

Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses-the ComIT-1 trial

Henrik Horndalsveen, Tine Norman Alver, Astrid Marie Dalsgaard, Lotte Victoria Rogg, Nina Helbekkmo, Bjorn Henning Gronberg, Tarje Onsoien Halvorsen, Christina Ramberg, Vilde Drageset Haakensen, Asa Kristina Ooejlert, Maria Moksnes Bjaanaes, Aslaug Helland

Summary: In this phase II trial, the combination of atezolizumab and stereotactic body radiotherapy was found to be safe and effective in treating advanced non-small-cell lung cancer patients. The study also highlighted the potential of circulating tumor DNA (ctDNA) as a biomarker for monitoring treatment response.

MOLECULAR ONCOLOGY (2023)

Article Oncology

Genomic ALK alterations in primary and relapsed neuroblastoma

Carolina Rosswog, Jana Fassunke, Angela Ernst, Birgid Schoemig-Markiefka, Sabine Merkelbach-Bruse, Christoph Bartenhagen, Maria Cartolano, Sandra Ackermann, Jessica Theissen, Mirjam Blattner-Johnson, Barbara Jones, Kathrin Schramm, Janine Altmueller, Peter Nuernberg, Monika Ortmann, Frank Berthold, Martin Peifer, Reinhard Buettner, Frank Westermann, Johannes H. Schulte, Thorsten Simon, Barbara Hero, Matthias Fischer

Summary: Genomic alterations of the ALK gene occur recurrently in neuroblastoma, with ALK mutations occurring in 10.5% of cases at diagnosis and increasing by 70% at relapse. However, the frequency of ALK amplifications does not change over the course of the disease. Regular monitoring of the genomic ALK status and evaluation of ALK-targeted treatment in intermediate-risk patients is recommended.

BRITISH JOURNAL OF CANCER (2023)

Article Biochemistry & Molecular Biology

Targeted epigenetic silencing of UCHL1 expression suppresses collagen-1 production in human lung epithelial cells

Dan-Dan Wu, Andy T. Y. Lau, Yan-Ming Xu, Marjan Reinders-Luinge, Mihaly Koncz, Antal Kiss, Wim Timens, Marianne G. Rots, Machteld N. Hylkema

Summary: Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) is highly expressed in smokers and its molecular mechanism in airway epithelium and its role in extracellular matrix (ECM) remodeling are not well understood. Our study showed that cigarette smoke extract (CSE) stimulated UCHL1 expression in vitro and the methylation status of the UCHL1 gene was negatively associated with UCHL1 transcription at specific sites in airway epithelium. Inhibition of UCHL1 activity prevented the TGF-beta 1-induced upregulation of the ECM gene COL1A1, and downregulation of UCHL1 by epigenetic editing reduced mRNA expression of COL1A1 and fibronectin. These findings suggest that UCHL1 may serve as a therapeutic target in fibrosis-related disease.

EPIGENETICS (2023)

Article Genetics & Heredity

Homozygous loss-of-function variants in FILIP1 cause autosomal recessive arthrogryposis multiplex congenita with microcephaly

Franziska Schnabel, Elisabeth Schuler, Almundher Al-Maawali, Ankur Chaurasia, Steffen Syrbe, Adila Al-Kindi, Gandham SriLakshmi Bhavani, Anju Shukla, Janine Altmueller, Peter Nuernberg, Siddharth Banka, Katta M. Girisha, Yun Li, Bernd Wollnik, Goekhan Yigit

Summary: This study reports five patients from three families with a disorder characterized by congenital joint contractures affecting multiple body parts, including shoulder, elbow, hand, hip, knee, and foot, as well as scoliosis, reduced palmar and plantar skin folds, microcephaly, and facial dysmorphism. Exome sequencing identified homozygous truncating variants in the FILIP1 gene in all patients. FILIP1 is involved in the regulation of filamin homeostasis and is essential for cortical cell migration and muscle cell differentiation.

HUMAN GENETICS (2023)

Article Oncology

The additional diagnostic value of virtual bronchoscopy navigation in patients with pulmonary nodules - The NAVIGATOR study

Birgitta I. Hiddinga, Dirk-Jan Slebos, T. David Koster, Lucie B. M. Hijmering-Kappelle, T. Jeroen N. Hiltermann, Hanneke Kievit, Anthonie J. van der Wekken, Gonda de Jonge, Rozemarijn Vliegenthart, Caroline Van De Wauwer, Wim Timens, Frederike Bensch

Summary: In this study, we evaluated the value of virtual bronchoscopy navigation in diagnosing solitary pulmonary nodules. The procedure had a good diagnostic yield and helped to prevent unnecessary invasive procedures and treatments without histological confirmation of cancer.

LUNG CANCER (2023)

Article Biochemistry & Molecular Biology

An integrated cell atlas of the lung in health and disease

Lisa Sikkema, Ciro Ramirez-Suastegui, Daniel C. Strobl, Tessa E. Gillett, Luke Zappia, Elo Madissoon, Nikolay S. Markov, Laure-Emmanuelle Zaragosi, Yuge Ji, Meshal Ansari, Marie-Jeanne Arguel, Leonie Apperloo, Martin Banchero, Christophe Becavin, Marijn Berg, Evgeny Chichelnitskiy, Mei-i Chung, Antoine Collin, Aurore C. A. Gay, Janine Gote-Schniering, Baharak Hooshiar Kashani, Kemal Inecik, Manu Jain, Theodore S. Kapellos, Tessa M. Kole, Sylvie Leroy, Christoph H. Mayr, Amanda J. Oliver, Michael von Papen, Lance Peter, Chase J. Taylor, Thomas Walzthoeni, Chuan Xu, Linh T. Bui, Carlo De Donno, Leander Dony, Alen Faiz, Minzhe Guo, Austin J. Gutierrez, Lukas Heumos, Ni Huang, Ignacio L. Ibarra, Nathan D. Jackson, Preetish Kadur Lakshminarasimha Murthy, Mohammad Lotfollahi, Tracy Tabib, Carlos Talavera-Lopez, Kyle J. Travaglini, Anna Wilbrey-Clark, Kaylee B. Worlock, Masahiro Yoshida, Maarten van den Berge, Yohan Bosse, Tushar J. Desai, Oliver Eickelberg, Naftali Kaminski, Mark A. Krasnow, Robert Lafyatis, Marko Z. Nikolic, Joseph E. Powell, Jayaraj Rajagopal, Mauricio Rojas, Orit Rozenblatt-Rosen, Max A. Seibold, Dean Sheppard, Douglas P. Shepherd, Don D. Sin, Wim Timens, Alexander M. Tsankov, Jeffrey Whitsett, Yan Xu, Nicholas E. Banovich, Pascal Barbry, Thu Elizabeth Duong, Christine S. Falk, Kerstin B. Meyer, Jonathan A. Kropski, Dana Pe'er, Herbert B. Schiller, Purushothama Rao Tata, Joachim L. Schultze, Sara A. Teichmann, Alexander Misharin, Martijn C. Nawijn, Malte D. Luecken, Fabian J. Theis, Yuexin Chen, James S. Hagood, Ahmed Agami, Peter Horvath, Joakim Lundeberg, Charles-Hugo Marquette, Gloria Pryhuber, Chistos Samakovlis, Xin Sun, Lorraine B. Ware, Kun Zhang

Summary: Single-cell technologies are used to study human tissues, but individual studies have limitations in terms of sample size and cell type definitions. The integrated Human Lung Cell Atlas (HLCA) combines 49 datasets from 486 individuals to create a comprehensive atlas of the human respiratory system. The HLCA provides new annotations for different cell types and allows for the identification of gene modules associated with demographic variables and changes in gene expression.

NATURE MEDICINE (2023)

Review Oncology

Modified study designs to expand treatment options in personalised oncology: a multistakeholder view

Christophe Le Tourneau, Fabrice Andre, Aslaug Helland, Linda Mileshkin, Warnyta Minnaard, Anja Schiel, Kjetil Tasken, David M. Thomas, Maria Luisa Veronese, Gonzalo Duran-Pacheco, Lada Leyens, Kaspar Rufibach, Marlene Thomas, Alwin Kraemer

Summary: Personalised oncology is becoming an essential part of clinical care, guided by molecular tumour profiles and next-generation sequencing technology. Clinical trials have shifted towards biomarker-driven studies of molecularly guided therapies and cancer immunotherapies, requiring a multistakeholder perspective. Innovative technologies and dynamic design methodologies will be necessary for efficient translation of scientific discoveries into clinical utility in the future of cancer clinical trials.

EUROPEAN JOURNAL OF CANCER (2023)

Editorial Material Respiratory System

Road map to improve the quality of lung cancer risk data

John K. Field

THORAX (2023)

暂无数据